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ABSTRACT
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GAS MEASUREMENT DEVICE

the amount of the neutral gas in the sample with a gas
measurement or gas detection device.
Other aspects of the invention will become apparent by
consideration of the detailed description and accompanying
drawings.

CROSS-REFERENCE TO RELATED
APPLICATION(S)
5

This application claims priority to U.S. Provisional Patent
Application No. 62/592,323, filed on Nov. 29, 2017, the
entire contents of which are fully incorporated herein by
reference.

BRIEF DESCRIPTION OF THE DRAWINGS

IO

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
This invention was made with govermnent support under
grant number DMR 1410192, awarded by the National
Science Foundation. The government has certain rights in
the invention.

15

BACKGROUND
20

Devices have been made for the detection and/or measurement of gases in aqueous systems, such as, for example,
those used for cell culture or for diagnostic or research
purposes. The detection and measurement of gases in such
systems may be important to understand how the system
behaves, and/or for monitoring and control of the system.
Such devices may be used to measure various gases.
For example, it may be advantageous to detect and or
measure Nitric Oxide (NO), in aqueous systems that are
being used for cell culture. NO, which is gaseous under STP
(standard temperature and pressure), is a free radical solute
that serves as a key signaling molecule in many cellular
processes. Nitric oxide has been shown to be a potent
inhibitor of platelet adhesions and activation, plays a role in
mediating the inflammatory process, and is an antibacterial
agent. NO has anti-apoptotic effects in endothelial cells,
lymphoma cells, ovarian follicles, cardiac myocytes and
hepatocytes, and pro-apoptotic properties in macrophages,
neurons, pancreatic ~-cells, thymocytes chondrocytes, and
hepatocytes. Some suggest that NO in low levels has a
protective and proliferative effect on cells, while at high
levels induces cell cycle arrest, senescence, and apoptosis.
As such, the presence and/or amount of NO in a cell culture
system may be very important. Moreover, devices that can
be used for cell culture while also detecting and/or measuring the amount of NO in the aqueous system may be
particularly advantageous.
Similarly, systems that allow for the detection and/or
measurement of gases in aqueous systems can be used to
observe the effects of gases on compounds and/or compositions contained within the aqueous system.
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SUMMARY
In one embodiment, the invention provides a device
including a first chamber, a second chamber, and a membrane permeable to neutral gases but impermeable to water
that is positioned between the first chamber and the second
chamber. The membrane includes a first layer including
PVDF and PDMS, and the PVDF has a plurality of pores at
least partially filled with at least some of the PDMS.
In another embodiment the invention provides a method
for detecting or measuring the amount of a neutral gas
associated with an aqueous solution, including: providing
the aqueous solution in the first chamber of the aforementioned device, collecting a sample of the neutral gas from the
second chamber of the device, and detecting or measuring
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This patent or application file contains at least one drawing executed in color. Copies of this patent or patent
application publication with color drawing(s) will be provided by the Office upon request and payment of the
necessary fee.
FIG. 1 shows a schematic of a gas measurement device
having two chambers separated by glass filter paper coated
with a layer of PDMS, a layer of polydopamine and a layer
of gelatin. Cells were cultured on the gelatin top layer;
cellular NO diffused in all directions; and once NO diffused
through the PDMS layer into the second (lower) chamber,
NO was carried into the NOA by a sweep gas for surface flux
measurement.
FIG. 2 shows images oflive human dermal fibroblast cells
(green, stained with calcein) and dead human dermal fibroblast cells (red, stained with ethidium bromide) on an area
of a membrane comprising PVDF and PDMS after 48 hours
of culture. Complete coating of the PVDF with PDMS was
not achieved on the area where the dead cells were observed.
FIG. 3 shows a particular embodiment of a device of the
present disclosure. It comprises two chambers (an upper and
a lower chamber) separated by a membrane that is permeable to neutral gases but impermeable to water that is
positioned between the first chamber and the second chamber. The membrane includes a first layer comprising PVDF
and PDMS, wherein the PVDF has a plurality of pores at
least partially filled with at least some of the PDMS. The first
(upper) chamber contains an aqueous solution which contains living cells (e.g., cells that have been cultured). Gas
associated with the cells, such NO, diffuses in all directions,
including crossing the membrane into the second (lower)
chamber of the device, which serves as a gas sampling
chamber from which cellular NO is collected (e.g., via a
sweep gas) and is detected and/or measured with a detector
(e.g., via chemiluminescence).
FIG. 4 shows an embodiment of a cell culture experiment
set-up. Cells were seeded within a first (upper) chamber, the
illustrated device was placed within a cell incubator for
normal cell culture, and it was coupled to sampling lines that
attached to a chemiluminescence NO detector.
FIG. 5 shows an illustration of how NO sampling can be
initiated and stopped at any time point during cell culture in
this particular embodiment.
FIG. 6 shows how a NO flux measurement was influenced
by the thickness of an NO permeable membrane. A SNAPPDMS disc, which released NO at a specific flux rate (arrow
A) was were inserted into aqueous solutions contained
within the upper chambers of gas measurement devices of
the present disclosure, where each device utilized a PVDF/
PDMS membrane of differing thickness. The trans-membrane NO flux was measured for devices having membranes
with a thickness of 17.3±3.2 µm (arrow B), 39.4±4.7 µm
(arrow C), 53.8±6.2 µm (arrow D), and 162.3±9.5 µm (arrow
E), respectively.
FIG. 7 shows an SEM image of the surface of the
foam-like structure of a membrane comprising PVDF and
PDMS.
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FIG. 8 shows an SEM image of the cross-section of the
foam-like structure of a membrane comprising PVDF and
PDMS.
FIG. 9 shows an embodiment of a two-chamber device
according to the present disclosure.
FIG. lOA, FIG. lOB, FIG. lOC, FIG. lOD, and FIG. lOE
show cross-section SEM images of different thicknesses of
PDMS membrane generated by multiply casting different
concentrations of PDMS solutions (for each cast, 72 µl/cm 2
solution was applied), scale bar: 150 µm. FIG. lOA shows
glass fiber filter paper; FIG. lOB shows 3 repeat of 1 g/10 ml
RTV-3140 PDMS cast; FIG. lOC shows 1 cast of 1 g/10 ml
RTV-3140 PDMS and2 repeat of 1 g/8 ml RTV-3140 PDMS
cast; FIG. lOD shows 1 cast of 1 g/10 ml RTV-3140 PDMS
and 3 repeat of 1 g/8 ml RTV-3140 PDMS cast; FIG. lOE
shows 1 cast of 1 g/10 ml RTV-3140 PDMS and 4 repeats
of 1 g/8 ml RTV-3140 PDMS cast.
FIG. 11 shows a graph of real-time nitric oxide (NO)
surface flux (normalized to the cell number) generated from
HD Fa with ( +) and without (-) stimulation cultured under
normal (5.5 mM) and high glucose (25 mM) conditions
measured with chemiluminescence detection using an NO
detection device disclosed herein.
FIG. 12A, FIG. 12B, FIG. 12C, and FIG. 12D show
images of cell viability detected by calcein AM and ethidium
bromide for primary human adult dermal fibroblasts cultured
in normal (5.5 mM) glucose conditions with and without
stimulation (FIG. 12A, FIG. 12B) and high glucose (25 mM)
conditions with and without stimulation (FIG. 12C, FIG.
12D), respectively. Scale bar 500 µm. The results are presented as the mean+/-standard deviation for n=3, *p<0.05.
FIG. 13 is a bar graph quantifying the results presented in
FIG. 12A, FIG. 12B, FIG. 12C, and FIG. 12D.
FIG. 14 is a bar graph showing total NO compared to
nitrite accumulation determined for HDFa with and without
stimulation under normal and high glucose conditions. For
N=3, there is statistically significant difference at p<0.05. *
normal glucose (LPS/IFN) vs. normal glucose (without
stimulation); $ normal glucose (LPS/IFN) versus high glucose (LPS/IFN), dots on each average bar indicate individual data points.
FIG. 15A and FIG. 15B are images showing immunofluorescent staining of CD90 (green) in HDFa cultured in
normal (FIG. 15A) and high glucose (FIG. 15B) conditions.
Cell nuclei are shown in blue. Scale bar 200 µm.
FIG. 16 is a western blot (left) and bar graph (right)
showing detection of iNOS expression by western blot
analysis ofHDFa cultured in normal (NG) and high glucose
(HG) conditions with (+) and without (-) stimulation. Predicted band size for iNOS 131 kD and observed band size
125 kD with iNOS and RAW 264.7 (M+ as positive controls.
MWM-molecular weight marker. Results are quantified in
the bar graph.

real-time fashion. Because of its biological and medical
significance, NO is used throughout this disclosure as an
exemplary neutral gas, but other neutral gases, such as N 2 (g),
CO 2 (g), O 2 (g), H 2 O 2 (g), CO(g), H 2 S(g), NH 3 (g), and combinations thereof, are explicitly contemplated herein.
The ability of a previous device ("CellNO trap") to
measure both the dose and the timing of NO generation has
been verified by the same inventors in Redox Biology, 8
(2016) 383-397 and "Systematic study of the biological
effects of nitric oxide (NO) using innovative NO measurement and delivery systems" Michigan Technological University, 2015, each incorporated herein by reference in their
entirety.
In brief, CellNO trap was verified by using a photosensitive NO releasing material, S-nitroso-N-acetylpenicillimine modified poly-dimethylsiloxane (SNAP-PDMS). Macrophages (RAW-264.7) cells were cultured in this device and
stimulated to demonstrate the ability to measure NO
released from cells in a real-time, continuous manner. Additionally, retinal epithelial (ARPE-19) cells, mouse vascular
smooth muscle (MOVAS) cells, vascular endothelial
(SVEC) cells, L-929 cell, and mouse primary tenocyte were
tested in the device to show general applicability of the
device to multiple cell types.
Although the CellNO trap device advanced the state of the
art, it suffers from some significant disadvantages. For
example, glass fiber filter paper was used in a water tight,
gas-permeable membrane (FIG. 1), but SNAP-PDMS could
not be easily applied to the membrane. Additionally, the
stiffness and smoothness of the membrane needed to be
markedly improved to, for example, improve adhesion of
cells to the membrane and the quality of fluorescent cell
images.
The unintuitive solution disclosed herein is to replace the
glass-fiber filter paper in the membrane with PVDF (polyvinylidene fluoride). While PVDF has the right mechanical
properties in terms of rigidity for this application, it was
unknown whether PVDF could be used for measuring
aqueous systems containing living cells, because PVDF is
notoriously toxic to cells. It also was unknown whether
coating PVDF with non-toxic PDMS would lead to cell
death, and in fact, when PVDF was incompletely covered
with PDMS, cell death was observed (see FIG. 2). Finally,
it was unclear whether a membrane comprising PVDF and
PDMS would be sufficiently gas permeable to allow for
measurement of gases associated with an aqueous system by
sampling the gas in a chamber on the opposite side of the
membrane.
In the disclosed device, a two-chamber structure (FIG. 3)
is designed to, for example, allow cells to grow in the first
(upper) chamber using conventional cell culturing media
and reagents and, at the same time, sample gas phase NO, for
example, in the second (lower) chamber. Once cellular NO
diffuses through the interface, NO can be carried by a sweep
gas into a nitric oxide analyzer (NOA) for continuous,
real-time measurement.
In certain embodiments, the device has more than two
chambers. In certain embodiments, the sweep gas is nitrogen
or ambient air. Alternately, there may be no sweep gas, such
as when a measurement or detection device is within the
second chamber. Typically, the second chamber is in fluid
communication with a gas detection or gas measurement
device.
In certain embodiments, the gas measurement or gas
detection device comprises a chemiluminescent detection
device, a electrochemical detection device, an optical detec-

DETAILED DESCRIPTION
Before any embodiments of the invention are explained in
detail, it is to be understood that the invention is not limited
in its application to the details of construction and the
arrangement of components set forth in the following
description or illustrated in the following drawings. The
invention is capable of other embodiments and of being
practiced or of being carried out in various ways.
Disclosed herein, among other things, is an easy and
reliable device for directly measuring a neutral gas associated with an aqueous system (e.g., the flux of a neutral gas,
such as NO(g), from cultured living cells) continuously in
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tion device, an infrared spectroscopy device, a mass specSince PDMS is not a good cell culture substrate, a
trometry device, a gas chromatography device, or a quartz
biocompatible polymer can be disposed on the membrane.
crystal microbalance.
Typically, an intermediate layer of adhesive is necessary
In certain embodiments, the first chamber contains an
between the PDMS and the biocompatible polymer.
aqueous solution. The aqueous solution may contain living 5
ECM component gelatin, for example, can be used for
cells. The aqueous solution may further contain a polymer.
surface treatment as a biocompatible polymer. To do this,
The polymer may be a hydrogel. The polymer may be
PDMS can be surface treated by coating with dopamine,
adapted to release nitric oxide.
which serves as an intermediate adhesive, and further with
Akey component of the disclosed device is a water-tight,
a gelatin solution applied over the polydopamine layer to
neutral gas permeable membrane used to separate the first 10 assist cell adhesion for cell culture. In this case, the layer of
chamber from the second chamber. To create the two indegelatin also protects the cells from being exposed to PVDF.
pendent chambers, the membrane at a minimum needs to be
In certain embodiments, the biocompatible polymer is
1) highly permeable to neutral gas (e.g. NO), 2) water
selected from the group consisting of gelatin, fibronectin,
impermeable, and 3) able to be readily fabricated. In certain
collagen, specific receptor proteins, antibodies, patterned
embodiments, the membrane must also be 4) compatible 15 DNA, electrospun fibers, cell adhesion matrixes or features,
with cell growth.
naturally or artificially laid down extracellular matrix, other
Polydimethoxylsiloxane (PDMS) is a preferred compocellular polymers, and combinations thereof.
nent of the membrane, because it has a large NO diffusion
In certain embodiments, the adhesive is selected from the
5
2
coefficient (up to 3.0xl0- cm /s), is highly hydrophobic
group consisting of polydopamine, organosilanes, PDMS,
such that it is impermeable to water, can be modified to be 20 modified PDMS, crosslinkers, carbodiimides, gluldahyde,
biocompatible, and is easy to cast into any shape. PDMS can
and combinations thereof.
be cast into layers up to 20 mm thick, such that NO diffuses
FIG. 4 illustrates the structure of an embodiment of the
through the membrane within one second. This ensures that
final device with a cell culture chamber on top and gas
the detection data directly reflects the real-time neutral gas
sampling chamber at the bottom. The assembled device can
released from (or consumed by) the cell layer.
25 be coupled to a chemiluminescence detector and placed
However, since PDMS itself is not stiff enough to provide
within an incubator for measuring real-time NO released
a mechanical support necessary for cell culture, PDMS was
from cells (FIG. 5).
cast over PVDF. The PVDF provides mechanical strength
The disclosed device achieves a real-time cellular gas
while the PDMS creates a gas permeable, water-tight chammeasurement without disturbing the cells under investigaber.
30 tion or deviating from standard cell culturing protocols. This
The PVDF has a porous structure (FIGS. 7 and 8). The
device opens up a huge potential for increasing understandPDMS permeates at least a portion of the pores of the PVDF.
ing of the role NO and other gases play in both normal and
In some embodiments, at least 99% of the pores of the PVDF
pathological conditions in a variety of tissues, and it could
are filled with PDMS.
potentially accelerate the ability to design NO releasing and
To achieve real-time NO measurement, NO gas molecules 35 generating therapeutic interventions by allowing quantitaneed to pass through the membrane as fast as possible, so
tive understanding of both the dose and temporal aspects of
that it can be detected in real-time. The Einstein-SmoluNO production in cells.
chowski equation describes the net molecule displacement,
li.x, versus time (t) as (ti.x)2=2Dt, where D represents the
EXAMPLES
diffusion coefficient.
40
To get a small t value, a thin interface and large D are
It should be kept in mind that the following described
required. To achieve this, a diluted RTV-3140/Sylgards
embodiments are only presented by way of example and
solution in toluene can be manually cast on PVDF layer by
should not be construed as limiting the inventive concept to
layer. A total of3 layers is preferred. Total polymer thickness
any particular physical configuration.
can be well controlled within 20 mm. To control and adjust 45
the thickness of polymer layer, different concentration of
Example 1
RTV-3140 solution (0.1 g/ml and0.125 mg/ml) and different
number of layers cast can be used.
Cell Culture and Treatment
In one embodiment, the total coverage of PDMS is about
Mouse macrophage cell line (RAW264.7) was kept in
4 mg per square centimeter. In another embodiment, the total 50 culture in conventional polystyrene petri-dish within comcoverage of PDMS is less than about 4 mg per square
plete DMEM (with 10% FBS and 1% penicillin-streptomycentimeter. In yet another embodiment, the total coverage of
cin). Cells were scraped off and reseeded into the first
PDMS is greater than about 4 mg per square centimeter.
(upper) chamber of the disclosed device. RAW264.7 culIn certain embodiments, the membrane has a thickness
tured within complete media was used as the negative
between about 15 µm and about 200 µm. The membrane may 55 control. Cells were stimulated with LPS and/or IFN-y.
have a total thickness between about 15 and about 200,
During NO measurement, different reagents which may
about 25 and about 190, about 35 and about 180, about 45
change cellular NO generation profile were administrated to
and about 170, about 55 and about 160, about 65 and about
cultured cells such that the final concentration of the
150, about 75 and about 140, about 85 and about 130, about
reagents are specified, including arginine (an additional 1
95 and about 120, or about 100 and about 115 µm. The 60 mM), the arginase inhibitor nor-NOHA (10 µM), and the
membrane have a total thickness less than or equal to about
NOS inhibitor L-NAME (50 µM).
200, about 175, about 150, about 125, about 100, about 75,
Direct Measurement of NO Release from Cells
about 50, about 25, about 20, or about 15 µm. The membrane
Cells were cultured within the first (upper) chamber using
may have a total thickness of about 15, 20, 25, 30, 35, 40,
standard cell culturing conditions until confluent, unless
45,50,55,60, 65, 70, 75, 80,85,90, 95,100,105,110,115, 65 otherwise stated. RAW264. 7 cells were then stimulated with
120,125,130,135, 140,145,150, 155,160,165, 170, 175,
LPS and/or IFN-y. The device containing cells was then
180, 185, 190, 195, or 200 µm.
placed into 37° C. 5% CO 2 incubator. The second (lower)
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chamber of the device was connected to NOA. Cellular NO
generation was measured in PPB/sec (parts per billion/s ),
converted to moles/sec, and normalized to surface area per
time to determine the surface flux of NO released by the cell
layer (nmole cm- 2 min- 1 ).
Cellular NO Probing by DAF
DAF-FM stain was dissolved m DMEM to the final
concentration of 10 µM. The DAF-FM contained media was
applied to cultured cells and incubated for 20 min at 37° C.
with 5% CO 2 . Media was removed and cells were washed
twice with PBS; then submerged in PBS and imaged using
either Zeiss AxioVert 200 M Apo Tome or Olympus BX51
fluorescent microscope.
Cell Image by Fluorescent Microscope
Cells were stained with live-dead assay reagents, 2 µM
calcein-AM and 2 µg/ml ethidium bromide, in DMEM
solution for 10 min. Fluorescently labeled cells were imaged
via Zeiss Axio Vert 200 M Apo Tome fluorescent microscope
or Olympus BX51 microscope.
Membrane SEM and AFM Imaging
The prepared semi-permeable membrane was cross-sectioned into 0.5 cm pieces. The membrane was platinum
coated (50 nm) and imaged with a Hitachi S-4700 FE-SEM.
Polydopamine and gelatin treated membrane was cut into
0.5 0.5 cm pieces for topographic image by Veeco Dimension 3000 at. force microscope. The aluminum reflex coated
cantilever (Tap300Al-G) was used with a resonance frequency of 300 kHz and a force constant of 40 Nim.
Statistical Analysis
The data was analyzed by either student's t-test or oneway analysis of variance. All statistical assays were achieved
through R programming, unless specifically noted.
Fabrication of PVDF Membrane
First, a mixture of Dow Coming Sylgard 184 PDMS base
and curing agent (10:1, w/w) dissolved in hexane was
vortex-mixed to form 1:30 (w/v) PDMS solution.
Then, 1 mL of freshly prepared Sylgard solution was
manually cast onto a 5 cmx5 cm square of PVDF membrane
(Bio-Rad Immun-Blot for Protein Blotting) and allowed to
air dry. This was repeated for a total of 3 times.
After the organic solvent had air dried, the membrane was
carefully transferred to a drying oven at 50° C. overnight to
cure the Sylgard polymer.
The composite membrane was then cut into a circle to fit
inside a 60 mm diameter cell culture plate.
Then, the membrane was attached to the cell culture plate
that had had its bottom removed (a 46 mm dia. circle was cut
from the center of the bottom of the culture dish, leaving a
3 mm wide rim on the inside of the dish to which the
membrane is attached to serve as the bottom of the culture
dish) by wetting the culture dish rim with toluene and
pressing the membrane to seal in softened polystyrene.
Then, the lower chamber was fabricated by drilling 2
holes in the sides of a second culture dish at 90° from each
other (90-120° was used and confirmed to be sufficient) and
epoxying 2 frits (Male luer lock barbs, 1/s'' (3.2 mm) ID) into
the holes. The epoxy was loctite 2-min, 2-part epoxy.
Then, the chambers were assembled together by aligning
the upper and lower chambers and applying toluene dropwise to melt the plastic together.
Then, freshly prepared dopamine solution (2 mg/mL, in
Tris-HCl buffer pH=S.5) was applied into the upper chamber, soaking for 24 h (12 to 20 h was sufficient, and no more
than 24 h). The polydopamine coating needed exposure to
ambient oxygen. The volume of dopamine solution (about 5
mL) needed to cover the membrane; excess solution was
poured off and the surface was rinsed with DI water to

remove any extra polydopamine particles that formed. The
membrane was allowed to air dry.
Then, the chamber was sterilized by either ethylene oxide
sterilization (24 h). Alternatively, the plate can be sterilized
by filling with 70% ethanol for 15 min followed by 30 min
of air drying and 1 hour of exposure to UV light in a bio
safety cabinet.
The dopamine-coated membrane in the plate was then
treated with a solution of gelatin (2 mg/mL Bio-Rad EIA
Grade Reagent Gelatin, cat #170-6537, prepared from DI
water and can be stored at 4 degree for up to one month) for
1 h. The volume of gelatin solution (about 5 mL) needed to
cover the bottom of the plate. Excess solution was poured
off. The device was air dried for 1 hour and then ready for
cell culture use.
Two-Chamber NO Delivery Device Design
A NO delivery set-up was designed to achieve controlled,
localized NO delivery (FIG. 9). Cells were grown on the
membrane of the NO measurement system and NO releasing
polymers were applied to the cultured cells from the other
side of the membrane according to specific needs and then
removed so that the NO flux was zero after a defined
delivery time. By connecting this system to a chemiluminescence detector, actual NO delivered to the cells could be
monitored. Ethidium bromide was introduced to label dead
or dying cells for better understanding the cell status.
However, while RTV-3140 and glass fiber filter paper
were used to fabricate the NO permeable but water tight
gas-permeable NO membrane, there were some issues associated with the NO permeable membrane, including NO
releasing polymer SNAP-PD MS could not be easily applied
to the membrane and the quality of the fluorescent cell image
and the stiffness of the produced film needed to be markedly
improved for adhesive cells. Thus, the design of the NO
measurement device was significantly altered.
Sylgard PDMS replaced RTV-3140 and reproducibly generated stiffer composite membranes. Glass-fiber filter paper
was replaced by PVDF (polyvinylidene fluoride) membrane
(pore size 2 µm). Compared with glass-fiber filter paper,
PVDF has a finer fiber structure. After PDMS polymer was
cast, the produced membrane displayed a more homogeneous and smooth surface, which is very important for
fluorescent imaging. To manufacture the membrane, the
mixture ofSylgardPDMS base and curing agent (10:1, w/w)
dissolved in hexane was vortex-mixed to form 1:20 (w/v)
PDMS solution. The solution was manually cast onto the
PVDF membrane (72 µl/cm 2 /cast) and air-dried. Three layers were cast to form a usable membrane. After the organic
solvent was air-dried, the membrane was carefully transported into 52° C. heating oven for overnight curing. The
micro structure of the produced gas-permeable membrane
was examined by SEM, shown in FIGS. 7 and 8.
NO Delivery Device Fabrication
To manufacture the delivery device, a semipermeable
membrane was attached to plastic boxes to form the upper
chamber of the device for cell culture, as shown in FIG. 9.
Dopamine solution (1 mg/ml, in Tris-HCl buffer pH=S.5)
was applied into the upper chamber, soaking for 24 h to
increase PDMS hydrophilicity; the chamber was ethylene
oxide sterilized and top treated with 2 mg/ml gelatin solution
for 1 h to facilitate cell adhesion. Then the device was ready
for cell culture. The lower chamber was produced by adding
2 ports onto a plastic box, so that the device could be easily
coupled into an NOA sampling line. Once the two chambers
were placed together, with the SNAP-PDMS polymer disk
attached directly under the membrane, NO was delivered
into the upper chamber at a specified flux, which was
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simultaneously being quantified through sampling NO from
the lower chamber, as shown the FIGS. 9 and 10, and
adjusted by the light source underneath the device.
Because the actual level of NO being delivered to the cells
was monitored in real-time, the NO generating rate could be
modulated in real-time by adjusting light energy impinged
on the polymer.
Since NO flux was mainly controlled by light, to create a
system that will generate homogeneous NO across the whole
NO source plane, a homogeneous light source was needed.
A 7x7 LED light array using (VAOL-5GSBY4, Mouser,
Tex.) LED bulb was fabricated. Blue light LED buds (593VAOL-5GSBY4, Mouser) were tin-soldered onto the
printed circuit board (PCB) to form a 7x7 LED array. An
LED diffuser (Bright View Tech, Morrisville, N.C.) was
placed over the LED array to homogenize the light. To
evaluate how homogeneous the light from the source plane
was, digital pictures of the light source plane were taken
with a black foam board placed on top of the light source to
avoid light leaking. ImageJ was used to analyze the digital
photo of the light source and the light intensity distribution.
The signal strength of each and every pixel of the picture
indicated a good homogeneity of the light source.
Controllable NO Delivery Device Build-Up
To confirm that the NO signal measured in the lower
chamber and the NO entering the upper chamber were
linearly related and the change was synchronized, two
identically calibrated NOAs were simultaneously used to
measure NO flux in real-time from both chambers; different
LED light intensity was used to manipulate the total NO flux
such that different NO levels in both chambers at different
time points were recorded in real-time. Linear regression
analysis was performed to validate the relationship between
the flux levels measured from both chambers.
NO released from SNAP-PDMS film either diffused into
the cell culture device or remained in the lower chamber.
The signal sampled by NOA did not actually represent the
NO flux experienced by the cells (the idea is the same with
the two-chamber NO measurement device).
The following experiment was completed to determine
the relationship between the sampled NO flux and NO flux
that the cultured cells experienced in the upper chamber. The
SNAP-PD MS disk (4 mm diameter, about 340 µm thick)
was placed under the PDMS membrane as the NO source.
SNAP-PD MS film was exposed under linearly changed light
intensity by changing LED drive current linearly to generate
different total NO fluxes while NO in both chambers were
recorded via two identically calibrated NOAs.
The NO flux pattern was recorded simultaneously (FIG.
6), and the linear regression analysis showed that NO signals
in both chambers did change linearly with each other
(R=0.9999). The difference of NO signals in the upper and
lower chamber was observed and the distribution rate was
determined by the geometry of NO releasing material,
membrane properties, and the attachment. These results
suggested that once there is NO generation in the lower
chamber by using SNAP-PDMS attached to the NO permeable membrane, cells cultured on the upper chamber experienced NO immediately without time delay, and the NO
signal captured from the lower chamber and the actual NO
delivered into the upper chamber were linearly related.

branes with consistent thickness were manufactured. It was
determined that a thinner polymer layer is better for NO
permeability without allowing water leakage. Meanwhile,
cell growth requires a certain level of overall membrane
stiffness. If a material is too soft, cell migration and proliferation will be affected, which may introduce significant
variability in behaviors of standard cell-line models.
Accordingly, the properties of PDMS/PVDF layer were
optimized.
To optimize the thickness of PDMS necessary to provide
water impermeability and still be thin enough to allow
necessary gas diffusion, different numbers of membrane
casting or different concentration of PDMS solutions were
applied, controlling the amount of PDMS deposited on the
membrane. RTV-3140 solutions were used to establish the
thickness requirements (1 g/10 ml toluene and 1.25 g/10 ml
toluene). By applying varying numbers of layers cast, NO
permeable composite membranes with different thicknesses
of PDMS were generated. FIG. 10 shows the control over
the PDMS layer thickness imaged by SEM; B to E have
different PDMS layer thicknesses, 17.3±3.2 µm, 39.4±4.7
µm, 53.8±6.2 µm, 162.3±9.5 µm, respectively.). This
ensured water impermeability, but allowed gas diffusion.
To optimize the necessary stiffness of the membrane,
Sylgard PDMS was used. Different from RTV-3140, the
PDMS polymer base and the curing agent are supplied
separately. By using a different base to curing agent ratio and
different curing temperature, a silicone elastomer with different stiffness can be produced. For the following adhesive
cell culture, a base: curing agent ratio of 10:1 (w/w) was
used, and the curing condition was set to 52° C. overnight.
This stiffness was appropriate for cell culturing and the
thickness had sufficient water impermeability and gas diffusion to functionally allow the device to work.
To confirm that the NO signal measured in the lower
chamber and the NO entering the upper chamber were
linearly related and the change was synchronized, two
identically calibrated NOAs were simultaneously used to
measure NO flux in real-time from both chambers. Different
LED light intensity was used to manipulate the total NO flux
such that different NO levels in both chambers at different
time points were recorded in real-time. Linear regression
analysis was performed to validate the relationship between
the flux levels measured from both chambers.

5

10

15

20

25

30

35

40

45

Example 3

50

55

60

Example 2
Control Over Membrane Properties
Since the sensitivity of the NO measurement method
relies on restricting the thickness of PDMS layer, mem-
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Detection of Nitric Oxide in Human Dermal Fibroblast Cells
Diabetic foot ulcers (DFU) are a major health problem
associated with diabetes mellitus. Impaired nitric oxide
(NO) production has been shown to be a major contributor
to the dysregulation of healing in DFU. However, the level
of impairment is not known primarily due to challenges with
measuring NO. The disclosed device was used to measure
NO production in human dermal fibroblasts under normal
and high glucose conditions.
Cell Culture and Chemical Supplies: Primary human
adult dermal fibroblasts (HDFa, ATCC® PCS-201-012™),
mouse macrophages (RAW 264.7), penicillin streptomycin,
fetal bovine serum (FBS), phosphate buffered saline (PBS),
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation assay kit and Dulbecco's modified
eagle medium (DMEM high glucose 4500 mg/L) were all
purchased from ATCC (Manassas, Va., USA). DMEM (no
glucose), sodium pyruvate and Hoescht dye were obtained
from Fischersci (Hanover Park, Ill., USA). Lipopolysaccharide pseudomonas aeroguinosa (LPS), Calcein-AM, pro-
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tease inhibitor cocktail, mouse nitric oxide synthase and
dopamine-RC! were purchased from Sigma-Aldrich (St.
Louis, Mo., USA). Ethidium bromide was acquired from
Invitrogen (Grand Island, N.Y., USA). Human recombinant
Interferon (hrIFN-y) was purchased from GenScript (Piscataway, N.J., USA). The primary and secondary antibodies
against CD90/Thyl (ab23894) protein and (iNOS)
(ab136918) were purchased from Abeam (Cambridge,
Mass., USA). The 7.5% SDS polyacrylamide gels and
gelatin were acquired from Bio-Rad (Hercules, Calif.,
USA). The Odyssey western blot starter kit 2 was obtained
from LI-COR (Lincoln, Nebr., USA). Silicone elastomer
base and curing agent (Dow Corning Sylgard® 184) were
obtained from ML Solar LLC (Campbell, Calif., USA).
Real Time NO Measurements from Primary Human Adult
Dermal Fibroblasts: Primary adult dermal fibroblasts at
passage 1 were cultured and expanded in conventional cell
culture plates (100 mm) in DMEM (high or normal glucose
levels), 10% FBS and 1% penicillin/streptomycin (complete
growth media). At confluency, the cells were reseeded in NO
detection devices at a density of0.25-lxl04 cells/cm 2 . The
NO detection devices were generated as described herein.
Briefly, silicone elastomer base and curing agent were
dissolved in hexanes, manually cast onto 5x5 cm square
polyvinylidene fluoride (PVDF) membranes and left to cure
in a 50° C. oven for 24 h. The modified membrane was cut
into a circle to fit into a 60 mm diameter cell culture plate
with the bottom removed forming the upper chamber. The
upper chamber was sealed by applying toluene to the edges
of the membrane and the plate. A second 60 mm plate with
drilled holes and plastic outlets attached was affixed to the
upper chamber using toluene and reinforced with epoxy
adhesive. The upper chamber was used for cell culture and
the lower chamber was used for gaseous transfer. To make
the device suitable for cell culture, freshly prepared dopamine solution in Tris-HCl buffer (2 mg/mL) was added to
the device and incubated for 12 h. The device was rinsed
several times and sterilized using 70% ethanol and ultraviolet light (1 h). Prior to cell culture, the device was coated
with gelatin solution (2 mg/mL). After 24-72 hours, the cell
culture media was changed and substituted with media
containing 40 µg/ml of LPS and 200 U/mL of hr!IFN-y or
complete growth media (control) under normal glucose (5.5
mM) and high glucose (25 mM) conditions. The device was
placed in a standard incubator (37 C, 65% humidity, 5%
CO 2 ) and was connected to a calibrated nitric oxide analyzer
(NOA) and the real-time NO release profile was measured
for 24 hours.
Cell Viability Assay. After 24 h, the live-dead assay was
carried out using 2 µM calcein AM, 2 µg/mL ethidium
bromide and 10 µg/mL Hoescht dye in DMEM media for
10-15 min. The cells were imaged and analyzed using an
Olympus fluorescent microscope (model BX51) and Image
J1 respectively.
Cell Proliferation Assays (MTT Assay): The fibroblast
cells were cultured in 96 well plates at a density of 10,000
cells per well in normal and high glucose cell culture
conditions and stimulated with 40 µg/mL and 200 U/mL of
LPS and IFN respectively. At the end of 24, 48 and 72 h,
MTT assay was performed according to the manufacturer's
instructions (Trevigen, 4890-025-K, Gaithersburg, Md.,
USA) with minor modifications. Briefly, the cell culture
media was replaced with 25 µL of the MTT reagent and
incubated for 4 h to allow the intracellular reduction of
soluble yellow MTT to insoluble formazan dye. The MTT
reagent was discarded and 100 µL oflsopropyl alcohol was
added to solubilize the dye. The absorbance was read at a

wave length of 570 nm using a VERSAmax tunable microplate reader model (Molecular devices, Sunnyvale, Calif.,
USA).
Nitrite Assay: After 24 h of measurement in the CellNO
trap device, the cell culture media from the cell samples
under normal and high glucose conditions were collected.
The triiodide assay was used to measure the nitrite accumulation in the media. Briefly, 50 µL of the media was added
to a vial containing a stirring solution of 300 µL of glacial
acetic acid and 120 µL of potassium iodide. The vial was
connected to a calibrated Sievers Nitric Oxide Analyzer 280i
(Zysense, LLC, Boulder, Colo., USA) and the NO produced
from the nitrite present in the media was measured and
normalized to the number of live cells.
Cell Characterization: Fibroblast cells at passage 2 were
cultured in 12 well plates at a cell density of lxl04 /cm2 in
normal and high glucose conditions. At confluency, the cells
were fixed in 4% paraformaldehyde for 10 min, rinsed three
times in phosphate buffered saline, incubated in blocking
buffer for 90 min followed by the primary antibody for 18
h at 4 ° C. The cells were rinsed three times in blocking
buffer and incubated for 1 h at room temperature with the
secondary antibody, stained with 4',6-diamidino-2-phenylindole (DAPI) and viewed under a fluorescent microscope.
Western Blot Analysis: Confluent HDFa cells were cultured in 100 mm diameter tissue culture dishes, stimulated
with 40 µg/mL of LPS and 200 U/mL IFN-y in normal and
high glucose conditions and incubated for 72 h. Mouse
macrophage cells RAW 264.7 were grown to confluency and
stimulated with 100 ng/mL of LPS for 18 hand served as the
positive control. The cells were quickly washed in ice cold
PBS, trypsinized, centrifuged and re-suspended in 200 µL of
RIPA buffer in the presence of protease cocktail inhibitors.
The cell lysates were incubated for 30 min on ice on a plate
shaker and centrifuged at 12,000 rpm for 20 min at 4 ° C. The
supernatant was collected and the protein concentration
determined for each sample using Bradford assay. An equal
amount of.loading buffer containing dithiothreitol was added
to each sample, boiled at 100° C. for 5 min and immediately
placed on ice for 2 min. About 5.63-9.37 µg of protein was
loaded in a 7.5% SDS-PAGE gel and separated by electrophoresis at 100 V for approximately 70 min. The proteins
were transferred to Immobilon®-FL PVDF membrane using
the Trans-Blot® Turbo™ Transfer System (Bio-Rad) for 7
min. The membrane was incubated in Odyssey blocking
buffer (TBS) for 60 min to block nonspecific binding sites
followed by incubation in TBS containing 0.2% oftween20
(TBS-T) and the iNOS antibody (1:1000 dilution) for 18 h
at 4 ° C. After that, the membrane was washed 4 times with
TBS (0.1% tween20) and incubated in TBS-T with the
secondary antibody (1 :20,000 dilution) for 1 h then extensively washed in TBS, visualized by LI-COR Odyssey
infrared imager and analyzed using Image Studio Lite
software Version 5.2. Statistical analysis was performed in
Microsoft Excel using one-way ANOVA followed by a
Bonferroni corrected t-test with statistical significance set at
a 95% confidence level (p<0.05).
Real-Time NO Detected under Normal and High Glucose
Conditions: Primary human adult dermal fibroblasts were
cultured in the NO detection device in either normal (5.5
mM) or high glucose (25 mM) media with and without
stimulation by the inflarnniatory cytokine interferon garnnia
(IFN-y) and bacterial endotoxin lipolysaccharide (LPS). The
NO production was measured for 24 h (FIG. 11). The cells
cultured in normal glucose media in the absence of stimulation showed a slight increase in NO release in the first 1 h
which peaked at 0.5x10- 12 (moles/min·cm2 )/10 5 cells and
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remained constant for 24 h. The HDFa cultured in high
glucose media without stimulation showed an increase in
NO production which peaked at 0.19xlo- 11 (moles/
min·cm2 )/105 cells and remained constant for 24 h. With
stimulation, there was an increase in the NO production for
cells cultured in normal glucose media, which peaked at
0.94x10- 11 (moles/min·cm2 )/10 5 cells and gradually
dropped to 0.6xl0- 11 (moles/min·cm2 )/10 5 cells. At 13 h, the
NOA was disconnected and recalibrated to confirm the
validity of the signal obtained (Arrow denoting the sudden
drop in curve in FIG. 11). The NO detected remained fairly
constant around 0.5x10- 11 (moles/min·cm2 )/105 cells up to
24 h. The NO release for cells cultured in high glucose
media followed a similar trend but with lower NO detected,
which peaked at 0.35x10- 11 (moles/min·cm2 )/105 cells at
approximately 4 h and gradually dropped to 0.8lxlo- 12
(moles/min·cm2 )/105 cells for 24 h.
The viability of the cells cultured in the NO detection
device in normal and high glucose culture conditions with
and without stimulation by IFN-y and LPS was analyzed by
the live/dead assay at the end of the real-time NO measurements. Cell viability detected by calcein AM and ethidium
bromide for primary human adult dermal fibroblasts (HD Fa)
cultured in normal (5.5 mM) glucose condition with and
without stimulation, (FIG. 12A,B) respectively and high
glucose (25 mM) condition without and with stimulation
(FIG. 12C,D) respectively. The cells maintained over 95%
cell viability in all the treatment groups (FIG. 13).
Nitric Oxide Detected from Nitrite Accumulation in the
Absence and Presence of Stimulation: After the real-time
NO measurements, the cell culture media was collected and
analyzed for nitrite using the triiodide assay (FIG. 14). The
nitrite present in the media is reduced in the presence of an
acid and nucleophile to produce NO that is measured via
chemiluminescence detection. Normal glucose conditions
without stimulation had significantly lower NO levels produced from nitrite compared to normal glucose conditions
with stimulation (0.73+/-0.05 versus 3.68+/-0.98 nmol/105
cells, p<0.05 for n=3). In high glucose conditions, there was
no statistical difference in the levels of NO detected without
stimulation compared to stimulation with LPS/IFN (0.91+/0.70 versus 4.26+/-2.11 nmol/105 cells). In the absence of
stimulation, the NO detected from nitrite in normal glucose
conditions compared to high glucose were not significantly
different (0.73+/-0.05 versus 0.91+/-0.70 nmol/105 cells).
Similarly, with stimulation, the NO detected from nitrite was
not statistically different in normal glucose compared to high
glucose 3.68+/-0.98 versus 4.26+/-2.11 nmol/10 5 cells.
Comparison of Real-Time NO Measurements and Nitrite
Accumulation: The total NO detected in real-time for the
HDFa was determined by integrating the area under the
curve (FIG. 11) and was compared to the NO inferred from
nitrite present in the cell culture media for the 4 treatments
groups (FIG. 14). The results showed that the levels of
real-time NO detected in nmol/10 5 was significantly higher
for cells in normal glucose conditions with stimulation
(8.42+/-1.16 p<0.05 for n=3) compared to without stimulation (0.48+/-0.31 for n=3 p<0.05). Similarly, under identical conditions, nitrite accumulation was significantly
higher in normal glucose with stimulation (3.68+/-0.98)
compared to absence of stimulation (0.73+/-0.05 for n=3
p<0.05). It is interesting to note that there was a higher direct
NO measured compared to nitrite. However, high glucose
conditions did not show the same trend. The levels of
real-time NO detected with stimulation were not statistically
different from levels of real-time NO without stimulation
(3.26+/-0.79 and 2.85+/-0.91 nmol/10 5 cells respectively).

The NO levels obtained from nitrite measurement depicted
a similar trend as the real-time NO measured, with no
statistical difference in high glucose conditions with stimulation compared to high glucose without stimulation
(4.26+/-2.11 and 0.91+/-0.70 nmol/10 5 cells). The real-time
levels of NO and nitrite detected in normal glucose conditions without stimulation were also not statistically different
from the real time NO detected from the cells in high
glucose conditions without stimulation (0.48+/-0.31 and
3.26+/-0.79 versus 0.73+/-0.05 and 0.91+/-0.70 nmol/105
cells respectively for n=3 p<0.05). Moreover, in normal
glucose conditions with stimulation, the levels of real-time
NO detected was significantly higher compared to high
glucose conditions with stimulation. The nitrite levels were
not statistically different. (8.42+/-1.16 and 3.26+/-0.79 versus 3.68+/-0.98 and 4.26+/-2.11 nmol/10 5 cells respectively).
Cell Characterization of HDFa Cultured in Normal and
High Glucose Conditions: Primary human adult dermal
fibroblasts cultured in normal and high glucose media were
assessed for the presence of CD90 (Thy-1), which is a
reliable molecular marker used to identify fibroblast cells in
culture. The HDFa maintained uniform staining for CD90
protein in normal (FIG. 15A) and high glucose conditions
(FIG. 15B) as well as the elongated and spindle shape that
is characteristic of confluent fibroblast cells.
Expression of iNOS Protein in HD Fa Cultured in Normal
and High Glucose Conditions: Stimulation of fibroblasts by
inflammatory cytokines and bacterial endotoxins has been
reported to upregulate the enzyme iNOS, which is directly
responsible for the production of NO in the cells. The levels
of iNOS in HD Fa were assessed in cells cultured in normal
and high glucose conditions with and without stimulation by
western blot. The results show that overall the iNOS enzyme
was present in all treatment groups and the protein level was
very low. Macrophage cell lysates (RAW 264.7) that are
known to express iNOS when stimulated with LPS and the
mouse iNOS enzyme protein were used as positive controls.
Faint iNOS bands can be seen in the human fibroblasts cells,
which appear at the same molecular weight as the iNOS in
macrophage cells and the mouse iNOS enzyme (FIG. 16).
There was no statistical difference in intensity found
between the groups at p<0.05 for n=3.
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Unless otherwise defined, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art. In case of
conflict, the present document, including definitions, will
control. Preferred methods and materials are described
below, although methods and materials similar or equivalent
to those described herein can be used in practice or testing
of the present invention. All publications, patent applications, patents and other references mentioned herein are
incorporated by reference in their entirety. The materials,
methods, and examples disclosed herein are illustrative only
and not intended to be limiting.
In its broadest definition, the term "dispersion" is
intended to include homogeneous solutions, heterogeneous
solutions, suspensions, colloids, aerosols, sols, emulsions,
gels, emulsions, foams, and combinations thereof. A dispersion may also refer to any one of the aforementioned phases,
or it may refer to any one of the possible combinations of the
aforementioned phases. For example, a dispersion could
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include homogeneous solutions, heterogeneous solutions,
suspensions, colloids, and emulsions but exclude aerosols
sols, and gels.
'
The terms "comprise(s)", "include(s)", "having", "has",
"can", "contain(s )", and variants thereof, as used herein, are
intended to be open-ended transitional phrases, terms, or
words that do not preclude the possibility of additional acts
?r structures. The singular forms "a", "and", and "the"
mclude plural references unless the context clearly dictates
otherwise. The present disclosure also contemplates other
embodiments "comprising", "consisting of', and "consisting
essentially of', the embodiments or elements presented
herein, whether explicitly set forth or not.
The conjunctive term "or" includes any and all combination_s of_ one or more listed elements associated by the
conJunct1ve term. For example, the phrase "an apparatus
comprising A or B" may refer to an apparatus including A
where B is not present, an apparatus including B where A is
not present, or an apparatus where both A and B are present.
The phrase "at least one of A, B, ... and N" or "at least one
of A, B, ... N, or combinations thereof' are defined in the
broadest sense to mean one or more elements selected from
the group comprising A, B, ... and N, that is to say, any
combination of one or more elements A, B, . . . or N
including any one element alone or in combination with one
or more of the other elements, which may also include, in
combination, additional elements not listed.
. ?1e ~odifier "about" used in connection with a quantity
1s mclus1ve of the stated value and has the meaning dictated
by the context (for example, it includes at least the degree of
error associated with the measurement of the particular
quantity). The modifier "about" should also be considered as
disclosing the range defined by the absolute values of the
two endpoints. For example, the expression "from about 2 to
about 4" also discloses the range "from 2 to 4". The term
"about" may refer to plus or minus 10% of the indicated
number. For example, "about 10%" may indicate a range of
9% to 11 %, and "about 1%" may mean from 0.9-1.1. Other
meaning~ of"about" may be apparent from the context, such
as roundmg off, so, for example "about 1" may also mean
from 0.5 to 1.4.
For the recitation of numeric ranges herein, each intervening number there between with the same degree of
precision is explicitly contemplated. For example, for the
range of 6-9, the numbers 7 and 8 are contemplated in
addition to 6 and 9, and for the range 6.0-7.0, the number
6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are
explicitly contemplated.
Various features and advantages of the invention are set
forth in the following claims.
What is claimed is:
1. A device comprising:
a first chamber;
a second chamber; and
a membrane permeable to neutral gases but impermeable
to water that is positioned between the first chamber
and the second chamber;
wherein the membrane includes a first layer comprising
PVDF and PDMS, wherein the PVDF has a plurality of
pores at least partially filled with at least some of the
PDMS;

wherein the membrane includes a second layer comprising a biocompatible polymer disposed on the first layer
between the first layer and the first chamber;
wherein the biocompatible polymer is selected from the
group consisting of gelatin, fibronectin, collagen, specific receptor proteins, antibodies, patterned DNA,
electrospun fibers, cell adhesion matrixes or features
extracellular matrix, and combinations thereof.
'
2. The device of claim 1, wherein the second layer is
adhered to the first layer with an adhesive.
3. The device of claim 2, wherein the adhesive is selected
from the group consisting of poly dopamine, organosilanes,
PDMS, modified PDMS, crosslinkers, carbodiimides, gluldahyde, and combinations thereof.
4. The device of claim 1, wherein the membrane has a
thickness between about 15 µm and about 200 µm.
5. The device of claim 1, wherein the second chamber is
in fluid communication with a gas detection or gas measurement device.
6. The device of claim 5, wherein the gas detection or gas
measurement device is adapted to measure or detect a gas
selected from the group consisting of NO(g) , N 2(g), CO 2(g),
O2(g)' H 2O 2(g)' CO(g)' H 2S(g)' NH 3 (g)' and combinations
thereof.
7. The device of claim 5, wherein the gas measurement or
gas detection device comprises a chemiluminescent detection device, an electrochemical detection device, an optical
detection device, an infrared spectroscopy device, a mass
spectrometry device, a gas chromatography device, or a
quartz crystal microbalance.
8. A method for detecting or measuring the amount of a
neutral _g~s associated with an aqueous solution, comprising:
prov1dmg the aqueous solution in the first chamber of the
device of claim 1;
collecting a sample of the neutral gas from the second
chamber of the device; and
detecting or measuring the amount of the neutral gas in
the sample with a gas measurement or gas detection
device.
9. The method of claim 8, wherein the gas measurement
or gas detection device is in the second chamber.
10. The method of claim 8, wherein the gas measurement
or gas detection device is outside the second chamber.
11. The method of claim 10, wherein collecting the
sample comprises moving the sample from the second
chamber to the gas measurement or gas detection device
using a sweep gas.
12. The method of claim 11, wherein the sweep gas
comprises nitrogen or ambient air.
13. The method of claim 8, wherein the aqueous solution
contains living cells.
14_- !he meth?d of claim 13, further comprising culturing
the hvmg cells m the aqueous solution.
15. The method of claim 8, wherein the aqueous solution
further contains a polymer.
16. The method of claim 15, wherein the polymer is a
hydrogel.
17. The method of claim 15, wherein the polymer 1s
adapted to release nitric oxide.

5

10

15

20

25

30

35

40

45

50

55

60

*

*

*

*

*

